<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136024">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01705080</url>
  </required_header>
  <id_info>
    <org_study_id>1201</org_study_id>
    <nct_id>NCT01705080</nct_id>
  </id_info>
  <brief_title>IntErnational Long-term Follow-up Study of Patients With Uncontrolled HyperTensioN</brief_title>
  <acronym>EnligHTN II</acronym>
  <official_title>IntErnational Non-randomized, Single-arm, Long-term Follow-up Study of Patients With Uncontrolled HyperTensioN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this post market clinical investigation is to further evaluate the safety and
      performance of the EnligHTN™ Renal Denervation System in the treatment of patients with
      uncontrolled hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>• Mean reduction in office Systolic Blood Pressure at six (6) months across all subjects post renal denervation and within sub-groups</measure>
    <time_frame>6 months post procedure</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of patients who experience a procedural related event</measure>
    <time_frame>30 days post procedure</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of renovascular safety as measured by new renal artery  stenosis or aneurysm at the site of ablation</measure>
    <time_frame>6 months, 2 years, and 5 years post procedure</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function change based on  eGFR</measure>
    <time_frame>6 months, 2 years, and 5 years post procedure</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ambulatory Blood Pressure parameters at 6 months</measure>
    <time_frame>6 months post procedure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in office Diastolic Blood Pressure at 6 months</measure>
    <time_frame>6 months post procedure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving office Systolic Blood Pressure &lt; 140 at 6 month visit</measure>
    <time_frame>6 months post procedure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Office Blood Pressure parameters at 12, 24, 36, 48, 60 months post denervation</measure>
    <time_frame>12, 24, 36, 48, 60 months post procedure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ambulatory Blood Pressure parameters at 12, 24, 36, 48, 60 months post denervation</measure>
    <time_frame>12, 24, 36, 48, 60 months post procedure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Hypertension</condition>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>Subjects receiving renal denervation</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EnligHTN</intervention_name>
    <description>Renal Denervation</description>
    <arm_group_label>Subjects receiving renal denervation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with uncontrolled hypertension
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is ≥ 18 years of age at time of consent

          -  Subject must be able and willing to provide written informed consent

          -  Subject must be able and willing to comply with the required follow-up schedule

          -  Subject has office Systolic Blood Pressure ≥ 140 mmHg at confirmatory visit

          -  Subject has a daytime mean Systolic Ambulatory Blood Pressure &gt; 135 mmHg within 90
             days prior to procedure

          -  Subject has established hypertension (diagnosed ≥12 month prior to baseline) and on a
             guideline based drug regimen at a stable and fully tolerated dose consisting of ≥ 3
             anti-hypertensive medications (including 1 diuretic) or subject has a documented drug
             intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB,
             Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3
             anti-hypertensive drugs.

        Exclusion Criteria:

          -  Subject has significant renovascular abnormalities such as renal  artery stenosis &gt;
             30%

          -  Subject has undergone prior renal angioplasty, renal denervation,  indwelling renal
             stents, and/or abdominal aortic stent grafts

          -  Subject has hemodynamically significant valvular heart disease as determined by study
             investigator

          -  Subject has a life expectancy less than 12 months, as determined by the Investigator

          -  Subject is participating in another clinical study which has the potential to impact
             their hypertension management (pharmaceutical/device/homeopathic)

          -  Subject is pregnant, nursing, or of childbearing potential and is not using adequate
             contraceptive methods

          -  Subject has active systemic infection

          -  Subject has renal arteries with diameter(s) &lt; 4 mm in diameter

          -  Subject has an estimated GFR &lt;15 mL/min per 1.73 m2 using the Modification of Diet in
             Renal Disease (MDRD) formula

          -  Subject had a renal transplant or is awaiting a renal transplant

          -  Subject has blood clotting abnormalities
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jane Johnson</last_name>
    <email>jjohnson10@sjm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephen Worthley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>61-7-31394000</phone>
      <email>Darren_walters@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Darren Walters, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>61-03-9342-8732</phone>
      <email>rod.warren@jcf.com.au</email>
    </contact>
    <investigator>
      <last_name>Rod Warren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>04050006000</phone>
      <email>Shard.shetty@health.wa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Sharad Shetty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Innsbruck Universitatsklinik fur Innere Medizin IV, Nephrologie und Hypertensiologie</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Mannhart</last_name>
      <phone>+43 512/504 258 56</phone>
      <email>Sabine.mannhart@uki.at</email>
    </contact>
    <investigator>
      <last_name>Gert Mayer, Univ Prof Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Ilkka.porsti@uta.fi</email>
    </contact>
    <investigator>
      <last_name>Ilkka Pörsti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Besancon</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Nicolas.meneveau@univ-fcomte.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas Meneveau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pierre Lantelme, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute Cardio. Paris-Sud-Institut Jacques Cartier</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hakim Benamer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU St. Etienne</name>
      <address>
        <city>St. Etienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Christophe.mariat@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe Mariat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Civil-Universittaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>olivier.morel@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier Morel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herz-und Diabeteszentrum</name>
      <address>
        <city>Bad Oeynhausen</city>
        <state>Nordrhein Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>05731/97-2121</phone>
      <email>seckert@hdz-nrw.de</email>
    </contact>
    <investigator>
      <last_name>Siegfried Eckert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bad Krozingen Herzzentrum</name>
      <address>
        <city>Bad Krozingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margarethe Welslau</last_name>
      <email>Margarethe.Welslau@univeritaets-herzzentrum.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Zeller, Prof Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kerckhoff Klinik</name>
      <address>
        <city>Bad Neuheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Helge Möllmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jüdisches Krankenhaus Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andreas Heinsius, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg GmbH</name>
      <address>
        <city>Coburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Johannes Brachmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinischen Einrichtungen der Universitat Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Philipp.kahlert@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Philipp Kahlert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatskliniken des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Michael.boehm@uks.eu</email>
    </contact>
    <investigator>
      <last_name>Michael Böhm, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Ingolstadt</name>
      <address>
        <city>Ingolstadt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Zackel</last_name>
      <phone>+ 0049 8418803539</phone>
      <email>Monika-zackel@klinikum-ingolstadt.de</email>
    </contact>
    <investigator>
      <last_name>Karlheinz Seidl, Prof MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Park-Krankenhaus Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Dierk.scheinert@parkkrankenhaus-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Dierk Scheinert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johannes Gutnberg University of Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas Munzel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Bramherzigen Bruder Trier</name>
      <address>
        <city>Trier</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Ke.hauptmann@bk-trier.de</email>
    </contact>
    <investigator>
      <last_name>Karl Hauptmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hippokration Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Konstantinos Tsioufis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Toscana Gabriele/Monasterio - Stabilimento Ospedaliero di Pisa</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sergio Berti, MD</last_name>
      <phone>+39.0585.493865</phone>
      <email>berti@ftgm.it</email>
    </contact>
    <contact_backup>
      <last_name>Marco Ciardetti, MD</last_name>
      <phone>+39.050.3152145</phone>
      <email>marco.ciardetti@ftgm.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Haga Ziwkenhuis Locatie Leyenburg</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hans Van Overhagen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+31-88-7555555</phone>
    </contact>
    <investigator>
      <last_name>Peter Blankenstijn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dunedin Public Hospital</name>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gerald Wilkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haukeland Universitetssykehus</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ingegjerd Sekse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Olavs University Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Knut Langlo, MD</last_name>
      <email>Knut.Asbjorn.Rise.Langlo@stolav.no</email>
    </contact>
    <investigator>
      <last_name>Rune Wiseth, M.D., PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Donsostia</name>
      <address>
        <city>Guipuzcoa</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 943 007 000</phone>
      <phone_ext>7148</phone_ext>
    </contact>
    <investigator>
      <last_name>Mariano DeBlas, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonas Multing, RN</last_name>
      <phone>+46 31 3428715</phone>
      <email>jonas.multing@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Bengt Rundqvist, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mel Lobo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northern General</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>William.McKane@sth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>William McKane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 13, 2014</lastchanged_date>
  <firstreceived_date>September 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Denervation</keyword>
  <keyword>Renal artery</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
